Ven Bio Partners LLC Elevation Oncology, Inc. Transaction History

Ven Bio Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.35 - $5.17 $615,413 - $1.35 Million	-261,878 Reduced 9.71%	2,434,255 $6.57 Million
Q1 2024 May 15, 2024	SELL	$0.59 - $5.13 $128,691 - $1.12 Million	-218,122 Reduced 7.48%	2,696,133 $13.8 Million
Q2 2023 Aug 14, 2023	BUY	$1.4 - $5.06 $1.47 Million - $5.3 Million	1,047,916 Added 56.15%	2,914,255 $4.43 Million
Q2 2022 Aug 15, 2022	SELL	$1.26 - $3.94 $934,703 - $2.92 Million	-741,828 Reduced 28.44%	1,866,339 $2.61 Million
Q2 2021 Aug 16, 2021	BUY	$11.44 - $13.57 $29.8 Million - $35.4 Million	2,608,167 New	2,608,167 $35.4 Million

45.4M

700

27.6K

Ticker ELEV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,300,900
Market Cap $12.3M
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...

Get notified when there are updates to the investment portfolio of Ven Bio Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Ven Bio Partners LLC with notifications on news.